P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression

Pluvio J. Coronado, Jose A. Vidart, Jose A. Lopez-asenjo, Maria Fasero, Vicente Furio-bacete, Javier Magrina, Manuel Escudero

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective: To investigate the prognostic value of p53 and HER-2/neu overexpression in endometrial cancer. Study Design: p53 and HER-2/neu immunostaining was performed in 114 paraffin-embedded specimens of endometrial cancer diagnosed and treated between 1990 and 1997. Nuclear p53 and membrane HER-2/neu immunostaining were used. Results: p53 and HER-2/neu overexpression was observed in 17 cases (14.9%) and in 19 cases (16.7%), respectively. In univariate analysis p53 (P < 0.001) and HER-2/neu (P = 0.018) overexpression had a positive correlation with a high risk of recurrence. In multivariate analysis, age (P < 0.001), FIGO stage (P < 0.001), differentiation (P = 0.013), non-endometrioid subtypes (P < 0.001) and p53 overexpression (P < 0.001), but not HER-2/neu overexpression, were independent prognostic indicators of recurrence. Simultaneous p53 and HER-2/neu overexpression made worse the prognostic (P < 0.001). Conclusions: p53 overexpression was an independent predictor of recurrent disease in endometrial cancer. HER-2/neu overexpression had a more limited effect but enhance the effect of p53.

Original languageEnglish (US)
Pages (from-to)103-108
Number of pages6
JournalEuropean Journal of Obstetrics Gynecology and Reproductive Biology
Volume98
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Endometrial Neoplasms
Recurrence
Nuclear Envelope
Paraffin
Multivariate Analysis

Keywords

  • Endometrial cancer
  • HER-2/neu
  • Immunohistochemistry
  • p53
  • Prognostic factors
  • Survival

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Coronado, P. J., Vidart, J. A., Lopez-asenjo, J. A., Fasero, M., Furio-bacete, V., Magrina, J., & Escudero, M. (2001). P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. European Journal of Obstetrics Gynecology and Reproductive Biology, 98(1), 103-108. https://doi.org/10.1016/S0301-2115(00)00562-5

P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. / Coronado, Pluvio J.; Vidart, Jose A.; Lopez-asenjo, Jose A.; Fasero, Maria; Furio-bacete, Vicente; Magrina, Javier; Escudero, Manuel.

In: European Journal of Obstetrics Gynecology and Reproductive Biology, Vol. 98, No. 1, 2001, p. 103-108.

Research output: Contribution to journalArticle

Coronado, Pluvio J. ; Vidart, Jose A. ; Lopez-asenjo, Jose A. ; Fasero, Maria ; Furio-bacete, Vicente ; Magrina, Javier ; Escudero, Manuel. / P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. In: European Journal of Obstetrics Gynecology and Reproductive Biology. 2001 ; Vol. 98, No. 1. pp. 103-108.
@article{7ed87bdf338848cf925ab3fe7ee6a002,
title = "P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression",
abstract = "Objective: To investigate the prognostic value of p53 and HER-2/neu overexpression in endometrial cancer. Study Design: p53 and HER-2/neu immunostaining was performed in 114 paraffin-embedded specimens of endometrial cancer diagnosed and treated between 1990 and 1997. Nuclear p53 and membrane HER-2/neu immunostaining were used. Results: p53 and HER-2/neu overexpression was observed in 17 cases (14.9{\%}) and in 19 cases (16.7{\%}), respectively. In univariate analysis p53 (P < 0.001) and HER-2/neu (P = 0.018) overexpression had a positive correlation with a high risk of recurrence. In multivariate analysis, age (P < 0.001), FIGO stage (P < 0.001), differentiation (P = 0.013), non-endometrioid subtypes (P < 0.001) and p53 overexpression (P < 0.001), but not HER-2/neu overexpression, were independent prognostic indicators of recurrence. Simultaneous p53 and HER-2/neu overexpression made worse the prognostic (P < 0.001). Conclusions: p53 overexpression was an independent predictor of recurrent disease in endometrial cancer. HER-2/neu overexpression had a more limited effect but enhance the effect of p53.",
keywords = "Endometrial cancer, HER-2/neu, Immunohistochemistry, p53, Prognostic factors, Survival",
author = "Coronado, {Pluvio J.} and Vidart, {Jose A.} and Lopez-asenjo, {Jose A.} and Maria Fasero and Vicente Furio-bacete and Javier Magrina and Manuel Escudero",
year = "2001",
doi = "10.1016/S0301-2115(00)00562-5",
language = "English (US)",
volume = "98",
pages = "103--108",
journal = "European Journal of Obstetrics and Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression

AU - Coronado, Pluvio J.

AU - Vidart, Jose A.

AU - Lopez-asenjo, Jose A.

AU - Fasero, Maria

AU - Furio-bacete, Vicente

AU - Magrina, Javier

AU - Escudero, Manuel

PY - 2001

Y1 - 2001

N2 - Objective: To investigate the prognostic value of p53 and HER-2/neu overexpression in endometrial cancer. Study Design: p53 and HER-2/neu immunostaining was performed in 114 paraffin-embedded specimens of endometrial cancer diagnosed and treated between 1990 and 1997. Nuclear p53 and membrane HER-2/neu immunostaining were used. Results: p53 and HER-2/neu overexpression was observed in 17 cases (14.9%) and in 19 cases (16.7%), respectively. In univariate analysis p53 (P < 0.001) and HER-2/neu (P = 0.018) overexpression had a positive correlation with a high risk of recurrence. In multivariate analysis, age (P < 0.001), FIGO stage (P < 0.001), differentiation (P = 0.013), non-endometrioid subtypes (P < 0.001) and p53 overexpression (P < 0.001), but not HER-2/neu overexpression, were independent prognostic indicators of recurrence. Simultaneous p53 and HER-2/neu overexpression made worse the prognostic (P < 0.001). Conclusions: p53 overexpression was an independent predictor of recurrent disease in endometrial cancer. HER-2/neu overexpression had a more limited effect but enhance the effect of p53.

AB - Objective: To investigate the prognostic value of p53 and HER-2/neu overexpression in endometrial cancer. Study Design: p53 and HER-2/neu immunostaining was performed in 114 paraffin-embedded specimens of endometrial cancer diagnosed and treated between 1990 and 1997. Nuclear p53 and membrane HER-2/neu immunostaining were used. Results: p53 and HER-2/neu overexpression was observed in 17 cases (14.9%) and in 19 cases (16.7%), respectively. In univariate analysis p53 (P < 0.001) and HER-2/neu (P = 0.018) overexpression had a positive correlation with a high risk of recurrence. In multivariate analysis, age (P < 0.001), FIGO stage (P < 0.001), differentiation (P = 0.013), non-endometrioid subtypes (P < 0.001) and p53 overexpression (P < 0.001), but not HER-2/neu overexpression, were independent prognostic indicators of recurrence. Simultaneous p53 and HER-2/neu overexpression made worse the prognostic (P < 0.001). Conclusions: p53 overexpression was an independent predictor of recurrent disease in endometrial cancer. HER-2/neu overexpression had a more limited effect but enhance the effect of p53.

KW - Endometrial cancer

KW - HER-2/neu

KW - Immunohistochemistry

KW - p53

KW - Prognostic factors

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0034865669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034865669&partnerID=8YFLogxK

U2 - 10.1016/S0301-2115(00)00562-5

DO - 10.1016/S0301-2115(00)00562-5

M3 - Article

VL - 98

SP - 103

EP - 108

JO - European Journal of Obstetrics and Gynecology and Reproductive Biology

JF - European Journal of Obstetrics and Gynecology and Reproductive Biology

SN - 0028-2243

IS - 1

ER -